Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib ...

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicated subsidiary company to ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to ...

Elix is a Japan-based AI drug discovery company with a mission to "Rethinking drug discovery," providing services to ...

To gain a better insight into Eisai’s current pipeline, its disease areas of importance and what Eisai are conducting beyond therapy development to tackle diseases we spoke with Gary Hendler.

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...

Review the current Eisai Co Ltd (4523:XTKS) dividend yield and history to decide if 4523 is the best investment for you.

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer.

Subscribe to our newsletter for the latest sci-tech news updates. The drugs in question—lecanemab, made by Eisai, and donanemab, made by Eli Lilly—have received significant attention, with headlines ...